Fármacos GLP1AR y trastorno por consumo de alcohol. ¿Representan una solución terapéutica definitiva o solo otra promesa incumplida?
DOI:
https://doi.org/10.20882/adicciones.2497Palabras clave:
Fármacos GLP-1R, Trastorno por consumo de alcoholResumen
Actualmente, la evidencia no respalda el uso de los agonistas GLP1-RA para el trastorno por consumo de alcohol. Aunque muestran un potencial prometedor -especialmente en casos resistentes o complejos-, los datos disponibles son aún preliminares, y su perfil de seguridad, aunque aceptable, no está exento de riesgos (como efectos gastrointestinales, pancreatitis o síntomas depresivos). Con varios ensayos clínicos en curso, esta situación podría cambiar en los próximos años. Sin embargo, ningún fármaco resolverá por sí solo un trastorno tan multifactorial. El abordaje del TCA deber seguir siendo integral, combinando intervenciones farmacológicas, psicológicas y sociales, e incorporando tanto la dimensión biológica como el contexto y las políticas de salud pública. Sin esta mirada amplia, los GLP-1RA corren el riesgo de convertirse en una promesa más no cumplida.Citas
Abebe, D. S., Lien, L. & Bramness, J. G. (2021). Effects of age and gender on the relationship between alcohol use disorder and somatic diseases: A national register study in Norway. BMJ Open, 11(11), e050608. https://doi.org/10.1136/BMJOPEN-2021-050608
Agabio, R., Lopez-Pelayo, H., Bruguera, P., Huang, S. Y., Sardo, S., Pecina, M., Krupitsky, E. M., Fitzmaurice, G. M. & Lin, Z. (2024). Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity. Pharmacological Research, 209. https://doi.org/10.1016/j.phrs.2024.107454
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M. & Jerlhag, E. (2023). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine, 93. https://doi.org/10.1016/j.ebiom.2023.104642
Arillotta, D., Floresta, G., Papanti Pelletier, G. D., Guirguis, A., Corkery, J. M., Martinotti, G. & Schifano, F. (2024). Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: Insights from Social Media using a mixed-methods approach. Brain Sciences, 14(6). https://doi.org/10.3390/BRAINSCI14060617
Bailey, A. J., Ingram, P. F., Howe, L. K. & Finn, P. R. (2022). Is lower severity alcohol use disorder qualitatively different than more severe manifestations? An evaluation of multivariate symptom clusters. Addiction, 117(6), 1598–1608. https://doi.org/10.1111/ADD.15785
Bora, A. & Fisette, A. (2023). The obese brain: Is it a matter of time? Trends in Endocrinology & Metabolism, 34(11), 691–693. https://doi.org/10.1016/J.TEM.2023.08.003
Bremmer, M. P. & Hendershot, C. S. (2024). Social Media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders. Journal of Studies on Alcohol and Drugs, 85(1), 5–11. https://doi.org/10.15288/JSAD.23-00318
Carminati, M., Tondello, M., Concina, A., Olgiati, P. & Zanardi, R. (2025). Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: A systematic review of potential benefits and risks. International Clinical Psychopharmacology. https://doi.org/10.1097/YIC.0000000000000595
Castillo-Carniglia, A., Keyes, K. M., Hasin, D. S. & Cerdá, M. (2019). Psychiatric comorbidities in alcohol use disorder. The Lancet. Psychiatry, 6(12), 1068. https://doi.org/10.1016/S2215-0366(19)30222-6
Chavez-Ugalde, Y., Jago, R., Toumpakari, Z., Egan, M., Cummins, S., White, M., Hulls, P. & De Vocht, F. (2021). Conceptualizing the commercial determinants of dietary behaviors associated with obesity: A systematic review using principles from critical interpretative synthesis. Obesity Science & Practice, 7(4), 473. https://doi.org/10.1002/OSP4.507
Chen, C., Zhou, R., Fu, F. & Xiao, J. (2023). Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: A real-world pharmacovigilance analysis. European Psychiatry, 66(1), e99. https://doi.org/10.1192/J.EURPSY.2023.2474
Chen, H., Liu, S., Gao, S., Shi, H., Yan, Y., Xu, Y., Fang, J., Wang, W., Chen, H. & Liu, Z. (2025). Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Scientific Reports, 15(1), 1–14. https://doi.org/10.1038/S41598-025-01206-9;SUBJMETA=137,163,2743,393,692,699;KWRD=DIABETES,OBESITY
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F. & Leggio, L. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 8(12). https://doi.org/10.1172/JCI.INSIGHT.170671
Commercial determinants of health. (n.d.). https://www.who.int/news-room/fact-sheets/detail/commercial-determinants-of-health
de Faria Moraes, B., André Pedral Diniz Leite, G., André Pedral Diniz Leite, G., Silveira, I. B., Lana, N. V. & Cançado, G. G. L. (2025). Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis. Drug and Alcohol Dependence, 275, 112840. https://doi.org/10.1016/J.DRUGALCDEP.2025.112840
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N., Gray, J. C., Lo Re, V., Fiellin, D. A., Kranzler, H. R., Koob, G. F., Justice, A. C., Vendruscolo, L. F., Rentsch, C. T. & Leggio, L. (2025). Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. Journal of Clinical Investigation, 135(9). https://doi.org/10.1172/JCI188314
Ghusn, W. & Hurtado, M. D. (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars, 12, 100127. https://doi.org/10.1016/J.OBPILL.2024.100127
Gomez-Escolar, A., Folch-Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Idrees Chaudhary, N., van der Meer, P. B. & Batalla, A. (2024). Current perspectives on the clinical research and medicalization of psychedelic drugs for addiction treatments: Safety, efficacy, limitations and challenges. CNS Drugs, 38(10), 771–789. https://doi.org/10.1007/S40263-024-01101-3
Griffiths, M. (2005). A “components” model of addiction within a biopsychosocial framework. Journal of Substance Use, 10(4), 191–197. https://doi.org/10.1080/14659890500114359;REQUESTEDJOURNAL:JOURNAL:IJSU20;WGROUP:STRING:PUBLICATION
Griffiths, M. D. (2008). The biopsychosocial and “complex” systems approach as a unified framework for addiction. Behavioral and Brain Sciences, 31(4), 446–447. https://doi.org/10.1017/S0140525X08004822
Hammarlund, R. A., Crapanzano, K. A., Luce, L., Mulligan, L. A. & Ward, K. M. (2018). Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders. Substance Abuse and Rehabilitation, Volume 9, 115–136. https://doi.org/10.2147/SAR.S183256
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D. & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/JAMAPSYCHIATRY.2024.4789
Holst, C., Tolstrup, J. S., Sørensen, H. J. & Becker, U. (2017). Alcohol dependence and risk of somatic diseases and mortality: A cohort study in 19 002 men and women attending alcohol treatment. Addiction, 112(8), 1358–1366. https://doi.org/10.1111/ADD.13799;WGROUP:STRING:PUBLICATION
Jensen, M. E., Klausen, M. K., Bergmann, M. L., Knudsen, G. M., Vilsbøll, T., Stove, C. & Fink-Jensen, A. (2025). Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption. Alcohol, Clinical and Experimental Research, 49(5), 1161–1165. https://doi.org/10.1111/ACER.70041;JOURNAL:JOURNAL:15300277;WGROUP:STRING:PUBLICATION
John, B. V., Bastaich, D., Marchetti, D., Perumalswami, P., Mustafa, M. Z. & Dahman, B. (2025). Association of GLP-1 receptor agonists with liver-related outcomes and all-cause mortality in patients with harmful alcohol use: A target trial emulation study. American Journal of Gastroenterology. https://doi.org/10.14309/AJG.0000000000003585
Kim, D. J., Jeong, H., Kim, S. Y., Kim, Y. H. & Yim, H. W. (2025a). Efficacy of non-invasive brain stimulation in reducing craving in patients with alcohol use disorder: Systematic review and meta-analysis. BMC Psychiatry, 25(1). https://doi.org/10.1186/S12888-025-06883-4
Kim, T. H., Lee, K., Park, S., Oh, J., Park, J., Jo, H., Lee, H., Cho, J., Wen, X., Cho, H., Kim, S. & Yon, D. K. (2025b). Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes, Obesity and Metabolism, 27(6), 3490–3502. https://doi.org/10.1111/DOM.16376
Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A. M. Ø., Zeeman, V. A., Johannsen, C. F., Lee, A., Thomsen, G. K., Macoveanu, J., Fisher, P. M. D., Gillum, M. P., Jørgensen, N. R., Bergmann, M. L., Poulsen, H. E., Becker, U., Holst, J. J., Benveniste, H., Volkow, N. D.,… Fink-Jensen, A. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 7(19). https://doi.org/10.1172/JCI.INSIGHT.159863
Köhne, S., Hillemacher, T., Glahn, A. & Bach, P. (2024). Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. Expert Opinion on Emerging Drugs, 29(3), 219–232. https://doi.org/10.1080/14728214.2024.2342951
Kruse Klausen, M., Thomsen, M., Wortwein, G. & Fink-Jensen, A. (2022). The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders. British Journal of Pharmacology, 179(4), 625. https://doi.org/10.1111/BPH.15677
Kuo, C. C., Li, C. H., Chuang, M. H., Huang, P. Y., Kuo, H. T. & Lai, C. C. (2025). Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder. Alimentary Pharmacology and Therapeutics, 61(8), 1343–1356. https://doi.org/10.1111/APT.70007;REQUESTEDJOURNAL:JOURNAL:13652036;WGROUP:STRING:PUBLICATION
Lähteenvuo, M., Tiihonen, J., Solismaa, A., Tanskanen, A., Mittendorfer-Rutz, E. & Taipale, H. (2025). Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry, 82(1), 94–98. https://doi.org/10.1001/JAMAPSYCHIATRY.2024.3599
Lohoff, F. W. (2022). Targeting unmet clinical needs in the treatment of alcohol use disorder. Frontiers in Psychiatry, 13, 767506. https://doi.org/10.3389/FPSYT.2022.767506/BIBTEX
Ma, H., Lin, Y. H., Dai, L. Z., Lin, C. S., Huang, Y. & Liu, S. Y. (2023). Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: A systematic review and network meta-analysis. BMJ Open, 13(3). https://doi.org/10.1136/BMJOPEN-2022-061807
MacKay, H., Gunasekara, C. J., Yam, K. Y., Srisai, D., Yalamanchili, H. K., Li, Y., Chen, R., Coarfa, C. & Waterland, R. A. (2022). Sex-specific epigenetic development in the mouse hypothalamic arcuate nucleus pinpoints human genomic regions associated with body mass index. Science Advances, 8(39). https://doi.org/10.1126/SCIADV.ABO3991
Maercker, A., Cloitre, M., Bachem, R., Schlumpf, Y. R., Khoury, B., Hitchcock, C. & Bohus, M. (2022). Complex post-traumatic stress disorder. The Lancet, 400(10345), 60–72. https://doi.org/10.1016/S0140-6736(22)00821-2
Mannes, Z. L., Shmulewitz, D., Livne, O., Stohl, M. & Hasin, D. S. (2021). Correlates of mild, moderate, and severe Alcohol Use Disorder among adults with problem substance use: Validity implications for DSM-5. Alcoholism: Clinical and Experimental Research, 45(10), 2118–2129. https://doi.org/10.1111/ACER.14701;JOURNAL:JOURNAL:15300277;WGROUP:STRING:PUBLICATION
Manthey, J., Gual, A., Jakubczyk, A., Pieper, L., Probst, C., Struzzo, P., Trapencieris, M., Wojnar, M. & Rehm, J. (2016). Alcohol use disorders in Europe: A comparison of general population and primary health care prevalence rates. Journal of Substance Use, 21(5), 478–484. https://doi.org/10.3109/14659891.2015.1063719
Martinelli, S., Mazzotta, A., Longaroni, M. & Petrucciani, N. (2024). Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug and Alcohol Dependence, 264. https://doi.org/10.1016/j.drugalcdep.2024.112424
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., Rhee, T. G., Cao, B., Teopiz, K. M., Wong, S., Le, G. H., Ho, R. & Kwan, A. T. H. (2025). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). Journal of Affective Disorders, 369, 922–927. https://doi.org/10.1016/J.JAD.2024.10.062
Mekonen, T., Chan, G. C. K., Connor, J., Hall, W., Hides, L. & Leung, J. (2021). Treatment rates for alcohol use disorders: a systematic review and meta-analysis. Addiction, 116(10), 2617–2634. https://doi.org/10.1111/ADD.15357;PAGE:STRING:ARTICLE/CHAPTER
Meshkat, S., Di Luciano, C., Swiderski, A., Li, G., Aguilar, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Greenshaw, A., Vermetten, E., Jetly, R., Dash, S., Agarwal, S. M., Swainson, J. & Bhat, V. (2025). Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: A systematic review. Brain and Behavior, 15(7). https://doi.org/10.1002/BRB3.70661
Miller, E. A., Capone, C., Eaton, E., Swift, R. M. & Haass-Koffler, C. L. (2025). Psychedelics for Alcohol Use Disorder: A narrative review with candidate mechanisms of action. CNS Drugs 2025, 1–22. https://doi.org/10.1007/S40263-025-01199-Z
Onyeka, I. N., Collier Høegh, M., Nåheim Eien, E. M., Nwaru, B. I. & Melle, I. (2019). Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: A systematic review and meta-analysis. Journal of Dual Diagnosis, 15(3), 192–206. https://doi.org/10.1080/15504263.2019.1619007
Pastor, A., Espelt, A., Villalbí, J. R., Moure, L., Fuentes, S., Shortt, N., Valiente, R., Borrell, L. N., Franco, M. & Sureda, X. (2022). Disponibilidad y promoción de alcohol según la tipología de los locales y las condiciones socioeconómicas del área. Adicciones, 34(1), 23–36. https://doi.org/10.20882/ADICCIONES.1367
Patterson Silver Wolf, D. A., Dulmus, C. N., Wilding, G. E., Yu, J., Barczykowski, A. L., Shi, T., Diebold, J. R., Harvey, S. J., Tomasello, N. M. & Linn, B. K. (2022). Treatment Resistant Alcohol Use Disorder. Alcoholism Treatment Quarterly, 40(2), 205–216. https://doi.org/10.1080/07347324.2021.1989994
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M. & Winzeler, B. (2023). Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight, 8(22). https://doi.org/10.1172/JCI.INSIGHT.170419
Puddephatt, J. A., Irizar, P., Jones, A., Gage, S. H. & Goodwin, L. (2022). Associations of common mental disorder with alcohol use in the adult general population: A systematic review and meta-analysis. Addiction, 117(6), 1543–1572. https://doi.org/10.1111/ADD.15735
Qeadan, F., McCunn, A. & Tingey, B. (2025). The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction, 120(2), 236–250. https://doi.org/10.1111/ADD.16679
Quddos, F., Hubshman, Z., Tegge, A., Sane, D., Marti, E., Kablinger, A. S., Gatchalian, K. M., Kelly, A. L., DiFeliceantonio, A. G. & Bickel, W. K. (2023). Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports, 13(1), 1–12. https://doi.org/10.1038/S41598-023-48267-2;SUBJMETA=2811,308,477,575,631,692;KWRD=HUMAN+BEHAVIOUR,TRANSLATIONAL+RESEARCH
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y. & Cheng, N. (2025). Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis. Scientific Reports, 15(1), 24103. https://doi.org/10.1038/S41598-025-09807-0
Ringel, M. M. & Ditto, P. H. (2019). The moralization of obesity. Social Science & Medicine, 237, 112399. https://doi.org/10.1016/J.SOCSCIMED.2019.112399
Rise, J. & Halkjelsvik, T. (2019). Conceptualizations of addiction and moral responsibility. Frontiers in Psychology, 10(JUN), 459408. https://doi.org/10.3389/FPSYG.2019.01483/BIBTEX
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M. & Ratziu, V. (2025). Phase 3 Trial of semaglutide in metabolic dysfunction–associated steatohepatitis. New England Journal of Medicine, 392(21), 2089–2099. https://doi.org/10.1056/NEJMOA2413258/SUPPL_FILE/NEJMOA2413258_DATA-SHARING.PDF
Schoepf, D. & Heun, R. (2015). Alcohol dependence and physical comorbidity: Increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England. European Psychiatry, 30(4), 459–468. https://doi.org/10.1016/J.EURPSY.2015.03.001
Scientists propose obesity is a neurodevelopmental disorder | BCM. (n.d.). https://www.bcm.edu/news/scientists-propose-obesity-is-a-neurodevelopmental-disorder
Sharma, P., Buddhavarapu, V., Dhillon, G., Verma, R. K., Devadoss, R., Raynor, J., Munjal, R., Grewal, H. & Kashyap, R. (2024). Glucagon-like peptide-1 receptor agonists: Are they as good as they seem? A systematic review of severe adverse effects. Endocrines 2024, Vol. 5, Pages 323-333, 5(3), 323–333. https://doi.org/10.3390/ENDOCRINES5030023
Shefer, G., Marcus, Y. & Stern, N. (2013). Is obesity a brain disease? Neuroscience and Biobehavioral Reviews, 37(10), 2489–2503. https://doi.org/10.1016/j.neubiorev.2013.07.015
Skarstein, S., Lien, L. & Abebe, D. S. (2023). The burden of somatic diseases among people with alcohol- and drug use disorders are influenced by mental illness and low socioeconomic status. A registry-based cohort study in Norway. Journal of Psychosomatic Research, 165, 111137. https://doi.org/10.1016/J.JPSYCHORES.2022.111137
Subhani, M., Dhanda, A., King, J. A., Warren, F. C., Creanor, S., Davies, M. J., Eldeghaidy, S., Bawden, S., Gowland, P. A., Bataller, R., Greenwood, J., Kaar, S., Bhala, N. & Aithal, G. P. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: A systematic review. EClinicalMedicine, 78, 102920. https://doi.org/10.1016/J.ECLINM.2024.102920
Sugiyama, Y., Matsushima, M. & Yoshimoto, H. (2020). Association between alcohol consumption/alcohol use disorders and patient complexity: A cross-sectional study. BMJ Open, 10(8), e034665. https://doi.org/10.1136/BMJOPEN-2019-034665
US Food and Drug Administration. (n.d.). FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ | FDA. 15/08/2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
Villalbí, J. R., Espelt, A., Sureda, X., Bosque-Prous, M., Teixidó-Compañó, E., Puigcorbé, S., Franco, M. & Teresa Brugal, M. (2019). Entorno urbano de alcohol: Un estudio sobre disponibilidad, promoción y visibilidad del consumo en barrios de Barcelona. Adicciones, 31(1), 33–40. https://doi.org/10.20882/ADICCIONES.950
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C. & Xu, R. (2024). Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study. Molecular Psychiatry, 29(8), 2587–2598. https://doi.org/10.1038/S41380-024-02498-5;SUBJMETA=476,5,692,699;KWRD=ADDICTION,PSYCHIATRIC+DISORDERS
Witkiewitz, K., Wilson, A. D., Pearson, M. R., Montes, K. S., Kirouac, M., Roos, C. R., Hallgren, K. A. & Maisto, S. A. (2019). Profiles of recovery from alcohol use disorder at three years following treatment: Can the definition of recovery be extended to include high functioning heavy drinkers? Addiction, 114(1), 69–80. https://doi.org/10.1111/ADD.14403;CTYPE:STRING:JOURNAL
Wolstenholme, J. T., Duong, N. K., Brocato, E. R. & Bajaj, J. S. (2024). Gut-liver-brain axis and alcohol use disorder: Treatment potential of fecal microbiota transplantation. Alcohol Research: Current Reviews, 44(1). https://doi.org/10.35946/ARCR.V44.1.01
World Health Organization. (2025). The Global Health Observatory. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/alcohol-use-disorders-(15-)-12-month-prevalence-(-)-with-95-
Zheng, Y. J., Soegiharto, C., Au, H. C. T., Valentino, K., Le, G. H., Wong, S., Teopiz, K. M., Rhee, T. G., Guillen-Burgos, H. F., Cao, B. & McIntyre, R. S. (2025). A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: Potential therapeutic strategy for alcohol use disorder. Acta Neuropsychiatrica, 37. https://doi.org/10.1017/NEU.2025.6
